Di Yi Cai Jing·2025-08-21 00:19Group 1 - The core viewpoint indicates that the blood products industry is expected to maintain steady growth in the first half of 2025, with a notable increase in the proportion of domestic albumin batch approvals compared to the previous year [1] - The approval batches for factor products such as factor VIII and fibrinogen are growing rapidly, reflecting companies' ongoing expansion of their factor product pipelines [1] - Companies are actively advancing research and development pipelines for recombinant products and new immunoglobulins, with several products already approved or under review for market launch [1] Group 2 - The blood products industry is anticipated to achieve overall steady growth in the second half of the year, driven by stabilizing product prices, increased plasma collection, and performance contributions from new products [1] - Companies that are industry leaders and are expected to continue expanding plasma station resources through both organic growth and external integration should be closely monitored for sustained growth in blood product business [1]